Clinical Pharmacology – Biomolecular
Xiaofei Wang, PhD
Pharmacologist
U.S. Food and Drug Administration
Silver Spring, Maryland
With the development of cancer immunotherapy, the landscape of biomarkers is rapidly evolving. As an important component in precision medicine, various biomarkers are widely used to identify target patient population, optimize dosing regimen, and improve benefit risk profiles of cancer immunotherapy. This presentation will provide a general overview of integrating biomarkers into clinical development programs for cancer immunotherapies: CAR T cell therapy, oncolytic viruses, and monoclonal antibodies targeting PD-1 or PD-L1.